Figure 3
From: Polygenic susceptibility to prostate and breast cancer: implications for personalised screening
Change in proportion of individuals eligible for screening with increase in the known susceptibility variants. The likely percentage fewer individuals that would be eligible for screening under the personalised screening strategy as compared with the standard screening while detecting the same number of cases with increase in the percentage of the known susceptibility alleles. Prostate: compared with screening men 55–79; currently ∼24% of the variants known. Breast: compared with screening women 47–79; currently ∼9% of the variants known.
